Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Celgene Inc.
Indication:
Ulcerative Colitis
Last updated:
November 10, 2023
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy
Last updated:
November 3, 2023
Status:
Concluded with an LOI
Manufacturer:
BeiGene, Ltd.
Indication:
Chronic lymphocytic leukemia (CLL) in adult patients
Last updated:
November 2, 2023
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel
Last updated:
November 1, 2023
Tecartus (brexucabtagene autoleucel)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Acute lymphoblastic leukemia (ALL), B-cell precursor, in adult patients, relapsed or refractory
Last updated:
October 27, 2023
Status:
Concluded without agreement
Manufacturer:
Chiesi Canada Corporation
Indication:
Transfusional iron overload due to sickle cell disease or other anemias
Last updated:
October 27, 2023
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Systemic lupus erythematosus
Last updated:
October 25, 2023
Status:
Concluded with an LOI
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Unresectable or metastatic uveal melanoma in adult patients who are Human leukocyte antigen (HLA)-A*02:01-positive
Last updated:
October 23, 2023
Lutathera (lutetium 177 dotatate)
Status:
Concluded with an LOI
Manufacturer:
Advanced Accelerator Applications
Indication:
Unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)-positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance
Last updated:
October 17, 2023
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Episodic migraine in adults (prevention)
Last updated:
October 12, 2023